SCPL51 Antibody

Advanced Research Questions

How do assay discrepancies impact clinical trial outcomes for SSc-ILD?

Implication: ID remains critical for patient stratification in trials targeting ILD progression. CIA/LIA may require cutoff recalibration to improve prognostic utility .

What engineering strategies improve therapeutic anti-C5 antibodies like SKY59?

• pH-dependent binding: Engineered to enhance FcRn recycling (plasma half-life >30 days in primates) .

• Surface charge modulation: Reduced isoelectric point (pI) accelerates immune complex clearance, minimizing C5 accumulation ($P < 0.01$) .

• COSMO mutagenesis: 1,000+ variants screened via high-throughput PCR transfection for binding optimization .

Technical challenge: Balance between improving pharmacokinetics and avoiding immunogenicity requires iterative humanization and in silico epitope analysis .

Methodological Controversies

Why do anti-Scl-70 antibodies show assay-dependent clinical correlations?

• Antigen source: ID uses native calf thymus topoisomerase I, while CIA/LIA employ recombinant or peptide antigens lacking post-translational modifications .

• Cutoff variability: CIA/LIA thresholds (e.g., 20 U/mL vs. 40 U/mL) may exclude patients with low-titer, clinically significant antibodies .

Resolution: Standardize antigen sources across assays and validate against clinical endpoints (e.g., FVC decline ≥10%/year).